Physiotherapy beneficial for people with Parkinson's disease in the short term

September 20, 2012

(Medical Xpress)—Results from a systematic review and meta-analysis led by the University of Birmingham in the UK suggest that physiotherapy benefits people with Parkinson's disease in the short term (< 3 months).

The management of Parkinson's disease has traditionally centred on drug treatment, however, there has been increasing support for the inclusion of rehabilitation therapies, such as , to supplement pharmacological and neurosurgical treatment.

Dr Claire Tomlinson, from the University of Birmingham Clinical Trials Unit, and colleagues selected 39 including 1827 participants for review.  The review included trials assessing a variety of different physiotherapy methods used to treat participants including general physiotherapy, exercise, treadmill training and dance. 

Of the 18 potential physiotherapy outcomes assessed, physiotherapy resulted in improvements in nine areas.  For three outcomes (gait speed, the Berg balance scale and a clinician-rated disability scale) there is existing evidence to suggest that these improvements may be clinically meaningful to people with Parkinson's disease.  For example, demonstrated that with physiotherapy intervention they were able to walk faster or maintain their balance better compared to no intervention.

Dr Tomlinson, said: "This study indicates that physiotherapy could provide clinically meaningful benefits in the short term for people with . Further improved studies are needed; these will shed more light on how beneficial physiotherapy can be for patients in the longer term.  Once a larger and better quality of evidence is achieved, there might be scope for a recommendation for change in practice to be made."

Explore further: Falls prevention in Parkinson's disease

More information: Physiotherapy intervention in Parkinson's disease: systematic review and meta-analysis, published by the British Medical Journal (BMJ) 2012;345(7872).

Related Stories

Falls prevention in Parkinson's disease

October 12, 2011
A study carried out by the Primary Care Research Group at the Peninsula College of Medicine and Dentistry, supported by the National Institute for Health Research (NIHR) and NIHR PenCLAHRC, has analysed the results of an ...

Added benefit of fampridine is not proven

August 29, 2012
Fampridine (trade name Fampyra) has been approved in Germany since July 2011 for adult patients suffering from a higher grade walking disability (grades 4 to 7 on the EDSS disability status scale), as a result of multiple ...

Recommended for you

Singing may be good medicine for Parkinson's patients

August 11, 2017
(HealthDay)—Singing? To benefit people with Parkinson's disease? It just may help, a researcher says.

Tracing the path of Parkinson's disease proteins

August 4, 2017
As neurodegenerative disorders such as Parkinson's and Alzheimer's disease progress, misfolded proteins clump together in neurons, recruiting normal proteins in the cell to also misfold and aggregate. Cells in which this ...

Diabetes drug shows potential as disease-modifying therapy for Parkinson's disease

August 3, 2017
A drug commonly used to treat diabetes may have disease-modifying potential to treat Parkinson's disease, a new UCL-led study suggests, paving the way for further research to define its efficacy and safety.

Two new studies offer insights into gastrointestinal dysfunction in Parkinson's patients

July 31, 2017
Constipation is one of the most common non-motor related complaints affecting Parkinson's disease (PD) patients. Two important studies from the same research group published in the Journal of Parkinson's Disease expand the ...

New drug may treat and limit progression of Parkinson's disease

July 31, 2017
Researchers at Binghamton University have developed a new drug that may limit the progression of Parkinson's disease while providing better symptom relief to potentially hundreds of thousands of people with the disease.

A new insight into Parkinson's disease protein

July 28, 2017
Abnormal clumps of certain proteins in the brain are a prominent feature of Parkinson's and other neurodegenerative diseases, but the role those same proteins might play in the normal brain has been unknown.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.